MedImmune LLC
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination with Axitinib in Subjects with Advanced Renal Cell Carcinoma
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- AstraZeneca AB
- Target Recruit Count
- 93
- Registration Number
- 2023-509604-15-00
- Locations
- π«π·
Institut Gustave Roussy, Villejuif, France
πͺπΈInstitut Catala D'oncologia, L'hospitalet De Llobregat, Spain
πͺπΈHospital Del Mar, Barcelona, Spain
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: IPH5201Biological: durvalumabBiological: oleclumab
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04261075
- Locations
- π¨π
Research Site, Lausanne, Switzerland
Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Phase 2
Withdrawn
- Conditions
- Microsatellite-stable Colorectal Cancer
- Interventions
- Drug: Standard of Care - mFOLFOX6Drug: E1 - mFOLFOX and durvalumabDrug: E2 - mFOLFOX6, durvalumab and oleclumabDrug: E3 - mFOLFOX6, durvalumab and monalizumab
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT04145193
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Combination Product: cotadutide multidose pen injection
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 36
- Registration Number
- NCT04091373
- Locations
- πΊπΈ
Research Site, Daytona Beach, Florida, United States
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Phase 1
Terminated
- Conditions
- Metastatic Microsatellite-stable Colorectal Cancer
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT04068610
- Locations
- πͺπΈ
Research Site, Madrid, Spain
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Drug: MEDI0382 high doseDrug: MEDI0382 low doseDrug: Placebo for MEDI0382 low doseDrug: Placebo for MEDI0382 high dose
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 74
- Registration Number
- NCT04019561
- Locations
- π΅π·
Research Site, San Juan, Puerto Rico
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT03946800
- Locations
- πͺπΈ
Research Site, Pamplona, Spain
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- MedImmune LLC
- Registration Number
- NCT03903718
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: MEDI5395Biological: Durvalumab
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 39
- Registration Number
- NCT03889275
- Locations
- π¬π§
Research Site, London, United Kingdom
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Phase 2
Completed
- Conditions
- Stage III Non-small Cell Lung CancerUnresectable
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 189
- Registration Number
- NCT03822351
- Locations
- π¨π³
Research Site, Taichung, Taiwan